WO2005095445A1 - 新規塩基性抗菌ペプチド及びその利用 - Google Patents
新規塩基性抗菌ペプチド及びその利用 Download PDFInfo
- Publication number
- WO2005095445A1 WO2005095445A1 PCT/JP2005/005724 JP2005005724W WO2005095445A1 WO 2005095445 A1 WO2005095445 A1 WO 2005095445A1 JP 2005005724 W JP2005005724 W JP 2005005724W WO 2005095445 A1 WO2005095445 A1 WO 2005095445A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cell growth
- peptide
- cell
- antibacterial
- basic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
Definitions
- the present invention relates to a novel basic antibacterial peptide, and use of the basic antibacterial peptide as an antibacterial agent and a cell growth promoter.
- Organisms have various defense mechanisms in order to protect themselves against microorganisms in the outside world.
- One of them is an antimicrobial peptide (Dental Diamond 26, No.356, 85-90) , 2001). Since such antimicrobial peptides are originally produced by the organism itself, they have a very small side effect or inhibitory effect on the living body and have a broad antibacterial spectrum with bacteria (including gram positive and negative) and fungi. As a result, it is gaining great hope as an alternative to antibiotics.
- antimicrobial peptides examples include histatin, defensin, ratatoferrin, and ratatopherin, which is a degradation product of ratatoferin (
- Lactoferrcin naturally occurring antimicrobial peptides such as magainin, cecropin, melititin, and mequilitin (maculatin), and Dhvar4 and Dhvar5 synthesized as histatin derivatives by the Dutch ACTA group.
- antimicrobial peptides such as magainin, cecropin, melititin, and mequilitin (maculatin)
- Dhvar4 and Dhvar5 synthesized as histatin derivatives by the Dutch ACTA group.
- histatins 1, 3, and 5 which are also composed of 38, 32, and 24 amino acid residues, respectively, are abundant in human saliva, and 50-450 / ⁇ in healthy adult adult saliva. It is present at a concentration of 8 ⁇ 1 (J. Biol. Chem., 273, 20438-20447, 1998).
- Histatin 5, which is considered to have the highest anti-candida activity, Statin 3 has an amino acid sequence common to 1 to 24 of the 32 amino acid residues.
- the defensin family is characterized as a cationic peptide in which six cysteine residues form three pairs of intramolecular disulfide bonds. Due to the combination of the disulfide bonds of these cysteine residues, the human defensin family is classified into two subfamilies, ⁇ - and j8-. Six different molecules have been reported for human a defensin, first discovered by Ganz et al. In 1985. Also, human
- human j8- defensin one 2 and are known cis Tin rich cationic peptides comprising even 41 amino acid residues force (Eur J Oral Sci; 109, 121-124, 2002) 0
- Human ⁇ -defensin 1 and human ⁇ -defensin 2 have strong ⁇ antibacterial activity ⁇ against Actinobacillus actinomycetemcomitan, which is one of the causative bacteria of periodontitis, It is known that periodontitis-causing bacteria such as intermedia ⁇ Campylobacter rectus ⁇ Fusobacteriumspecies and Eubacterium species ⁇ Treponema species also have antibacterial activity (Japanese Patent Application Laid-Open No. 2001-288105).
- Patents have recently disclosed various types of antimicrobial peptides in addition to those described above.
- JP-A-2-53799 and JP-A-5-271096 disclose an antimicrobial peptide derived from horseshoe toga
- JP-T-2-500084 discloses an antimicrobial peptide isolated from bee hemolymph.
- Japanese Patent Application Laid-Open Publication No. 6-80695 discloses an antimicrobial peptide isolated from ratatoferin hydrolyzate in Japanese Unexamined Patent Publication (Kokai) No. 6-80695.
- Japanese Patent Application Laid-Open No. Hei 8-119995 discloses an antimicrobial peptide (molysin) isolated from bodily fluid of silkworm
- Japanese Patent Application Laid-Open No. 10-1498 discloses an antimicrobial peptide isolated from fetal bovine serum
- Japanese Patent Application Laid-Open No. 2000-26499 discloses an antimicrobial peptide produced by the force beetle
- Japanese Patent Application Laid-Open No. 2000-217578 discloses an antimicrobial peptide derived from human plasma components
- Japanese Patent Publication No. 2003-267805 discloses that the trypsin digestive power of casein is also isolated and the antibacterial peptide power is isolated.
- Each of the antimicrobial peptides isolated from tryptic digests is disclosed!
- antimicrobial peptides are basic to neutral and amphiphilic. Microbial cell membranes or cell walls are much more negatively charged than living cells. Such a basic (high pi) property of such peptides is associated with (but not nonspecific) microbial cell membranes. It is considered necessary to promote selective initial binding. Therefore, it is known that many peptides, which have a low pi value and are hardly charged positively (+) in the physiological pH range, have high cytotoxicity even though they have antibacterial properties. Thus, antimicrobial peptides are secreted in response to exogenous microbial stimuli, inherently associated with innate immunity.
- Such peptides are known to exhibit antibacterial activity when the ionic strength of a saliva or the like is low and very strong in a solution (J. Biol. Chem., 273, 20438-20447, 1998; Biochim Biophys Acta., Dec 15; 1462 (l-2), 55-70, 1999).
- histatin 5 is known to lose antimicrobial activity at 20-50 mM PBS.
- ⁇ -defensin which is also produced by gingival fibroblasts and periodontal ligament cells, shows little antibacterial activity in tissues (Jpn. J. Med Mycol, 41, 77-81, 2000). This is thought to be due to the high ionic strength of tissue fluids and blood, which results in the loss of antibacterial activity.
- type III is mainly achieved by culturing autologous cells (especially stem cells), which are also collected from patients, in vitro and then multiplying and regenerating the regenerated tissues.
- autologous cells especially stem cells
- mesenchymal stem cells are grown in culture Z
- basic FGF basic fibroblast growth factor
- this basic FGF is very expensive, which makes mass culture and growth very expensive.
- Patent Document 1 JP-A-2-53799.
- Patent Document 2 JP-A-5-271096.
- Patent Document 3 Japanese Patent Publication No. 2-500084.
- Patent Document 4 JP-A-5-78392.
- Patent Document 5 JP-A-5-92994.
- Patent Document 6 JP-A-5-148295-7.
- Patent Document 7 JP-A-9-1124504.
- Patent Document 8 JP-A-9-1165342.
- Patent Document 9 JP-A-11-92375.
- Patent Document 10 JP-A-6-80695.
- Patent Document 11 JP-A-8-19995.
- Patent Document 12 JP-A-10-1498.
- Patent Document 13 JP-A-2000-26499.
- Patent Document 14 JP-A-2000-217578.
- Patent Document 15 JP-A-2001-288105.
- Patent Document 16 Japanese Patent Application Laid-Open No. 2002-179698.
- Patent Document 17 JP-A-2002-179699.
- Patent Document 18 Japanese Patent Publication No. 2002-503641.
- Patent Document 19 JP-T-2002-522556.
- Patent Document 20 JP-A-2003-52365.
- Patent Document 21 JP-A-2003-267805.
- Non-Patent Document 1 Dental Diamond 26, No. 356, 85-90, 2001.
- Non-Patent Document 2 FEBS Lett, 449, 105-110, 1999.
- Non-Patent Document 3 J. Biol. Chem., 261, 1177-1182, 1986.
- Non-Patent Document 4 J. Biol. Chem., 263, 7472-7477, 1988.
- Non-Patent Document 5 J. Dent. Res., 69, 2-6, 1990.
- Non-Patent Document 6 J. Biol. Chem., 273, 20438-20447, 1998.
- Non-Patent Document 7 Eur J Oral Sci; 109, 121-124, 2002.
- Non-Patent Document 8 J. Biol. Chem., 273, 20438-20447, 1998.
- Non-Patent Document 9 Biochim Biophys Acta., Dec 15; 1462 (1-2), 55-70, 1999.
- Non-Patent Document 10 Jpn. J. Med Mycol, 41, 77-81, 2000.
- An object of the present invention is to provide a novel antimicrobial peptide having extremely small side effects and inhibitory effects on living organisms and having useful activity, and to provide an antimicrobial agent or cell growth promotion of the antimicrobial peptide. To provide use as an agent.
- the present inventor has been eagerly searching for a novel antimicrobial peptide that solves the above-mentioned problems, and has found that the basic antimicrobial peptide having a novel amino acid sequence artificially designed by the present inventor has an effect on oral microorganisms. It has a broad spectrum and strong antibacterial properties, and has a strong bactericidal action, especially against bacterium mutans, and furthermore, this antibacterial peptide is useful for cells such as mesenchymal stem cells and fibroblasts. They have found that they have a growth promoting activity, and have completed the present invention.
- the novel antimicrobial peptide of the present invention comprises the amino acid sequence shown in SEQ ID NO: 1 in the sequence listing.
- the present invention relates to a derivative obtained by deleting, substituting, or adding one to several amino acids in the amino acid sequence of the antimicrobial peptide. And a basic antimicrobial peptide.
- the present invention also includes the use of the basic antimicrobial peptide of the present invention as an antibacterial agent or a cell growth promoter.
- antimicrobial peptides are secreted in response to exogenous microbial stimuli in association with innate immunity.
- Such peptides are known to exhibit low ionic strength, such as saliva, and very strong in solution, exhibiting antibacterial activity (J Biol Chem 273: 20438-47, 1998; Biochim Biophys Acta. 1999).
- histatin 5 are known to lose antimicrobial activity 20 ⁇ 50MMPBS.
- gingival fibroblasts and periodontal ligament cells also produce ⁇ -defensin, an antimicrobial peptide that has little antimicrobial activity in tissues (Shigeru Abe, Hideyo Yamaro; Biological defense against fungal infection, Jpn. J. Med Mycol, 41, 77-81, 2000). This is thought to be due to the high ionic strength of tissue fluids and blood, which results in loss of antibacterial activity. Has been obtained.
- the present inventor has conducted a synthesis of a natural antimicrobial peptide with a cell-proliferating action and an antibacterial peptide having an artificially designed amino acid sequence so far, and carried out its antibacterial action and cell-proliferation.
- an artificially designed peptide with a novel amino acid sequence, CFH8944
- the artificially designed peptide has a weak bactericidal effect on Candida yeast and a strong bactericidal activity on the mycobacterium myutans. As shown in Fig.
- the present inventors examined the cell growth effect of a peptide having a novel amino acid sequence that was artificially designed this time, and found that the peptide showed a cell growth effect on rat mesenchymal stem cells. As shown in FIG. 2, the present invention has been completed. Since those similar to the antimicrobial peptide of the present invention naturally exist in nature, when administered to an organism having a very small side effect or inhibitory effect on the living body, it can safely exert its effects, It is possible to avoid harm and side effects to the living body such as antibiotics.
- the antimicrobial peptide of the present invention is very inexpensive compared to basic FGF, and can be used as an inexpensive drug when used as a cell growth promoter.
- the antimicrobial peptide of the present invention has a broad spectrum and strong antibacterial properties against oral microorganisms, and can be used as an effective antibacterial agent against these microorganisms. Furthermore, it is expected that the possibility of the emergence of bacteria resistant to use as an antibacterial agent is very low at present because of the component of innate immunity.
- the present invention relates to (1) a basic antimicrobial peptide having the amino acid sequence shown in SEQ ID NO: 1 in the sequence listing, or a deletion of one to several amino acids in the amino acid sequence of the peptide.
- Antibacterial agents as active ingredients and (3) antimicrobial agents The antibacterial agent according to the above (2), which is a bactericide for living organisms, or the antibacterial agent according to the above (3), wherein (4) the oral microbial is a mutans bacterium.
- a cell growth promoting factor comprising the basic antimicrobial peptide according to (1), and (6) the cell growth promotion is mesenchymal stem cell or fibroblast cell growth promotion.
- the cell growth promoting factor described in (5) above and (7) the cell growth promotion of mesenchymal stem cells are promoted by the cell growth promotion of mesenchymal stem cells isolated from bone marrow of alveolar bone, palate or periosteum of alveolar bone.
- the cell growth promoting factor according to (5) or (6) above, wherein (8) promotion of fibroblast cell growth is gingival fibroblast cell growth.
- the present invention also provides (10) a cell growth method comprising promoting cell growth in vitro or in vivo by using the cell growth promoter described in (9) above, 11) The cell growth method according to the above (10), wherein the cell growth promotion in in vitro cell growth is cell growth promotion in mesenchymal stem cell cell growth, and (12) in vivo cell growth.
- the cell growth promotion in (1) is the promotion of growth of transplanted tissue cells in tissue transplantation.
- the novel antimicrobial peptide of the present invention can exert its efficacy safely when administered to an organism having extremely small side effects or inhibitory effects on living organisms, and also has the ability of the antimicrobial peptide of the present invention to exert its efficacy.
- the antimicrobial peptide of the present invention has a broad spectrum and strong antibacterial properties against oral microorganisms, and can be used as an effective antibacterial agent against these microorganisms. At present, it is expected that the possibility of the emergence of bacteria resistant to the use of this is extremely low because it is a component of innate immunity.
- the antimicrobial peptide of the present invention can be used as a cell growth promoter to promote effective cell growth in vitro or in vivo cell growth.
- the antimicrobial peptide of the present invention has the advantage that it can be provided at a low cost. It becomes possible to grow efficiently.
- the cell growth promoter of the present invention can be effectively used as a cell growth promoter at the time of tissue transplantation in actual clinical application in vivo, and, when viable, is used as a peptide having antimicrobial properties.
- the promotion of proliferation in the tissue after transplantation is very important from the viewpoint of prevention of postoperative infection and from the viewpoint of cancer.
- the present invention provides a basic antimicrobial peptide having the novel amino acid sequence shown in SEQ ID NO: 1 in the sequence listing, or one to several amino acids deleted, substituted or added in the amino acid sequence of the peptide.
- An antimicrobial agent comprising a basic antimicrobial peptide as a derivative, comprising the basic antimicrobial peptide, a pharmaceutically acceptable derivative thereof or a pharmaceutically acceptable salt thereof as an active ingredient, or the basic antimicrobial peptide.
- the present invention provides a cell growth promoter comprising a peptide.
- the microorganism to be subjected to the antibacterial action is not particularly limited.
- the microbes in the oral cavity having a strong antibacterial activity with the broad antibacterial peptide of the basic antibacterial peptide of the present invention are targeted. It can be mentioned as a microorganism.
- the bacterium mutans which is a cariogenic bacterium in which the basic antibacterial peptide of the present invention exhibits a particularly strong bactericidal action, can be mentioned as a microorganism of particular interest.
- the cells to be promoted by the cell growth promoter comprising the basic antimicrobial peptide of the present invention are not particularly limited, and include animal cells such as mesenchymal stem cells or fibroblasts as the cells to be promoted.
- the cells can be grown in vitro or in vivo using a cell growth promoter.
- Examples of the promotion of cell proliferation of mesenchymal stem cells include promotion of cell proliferation of mesenchymal stem cells (JP-A-2003-52365) isolated from bone marrow of alveolar bone, palate or periosteum of alveolar bone.
- examples of promotion of cell proliferation in in vivo cell proliferation include promotion of proliferation of transplanted tissue cells in tissue transplantation.
- specific examples of the cells to be promoted for cell proliferation of the present invention include bone marrow-undivided mesenchymal stem cells, skeletal muscle stem cells, hematopoietic stem cells, neural stem cells, liver stem cells, and adipose tissue.
- Stem cells such as woven stem cells, adipose precursor cells, vascular endothelial precursor cells, cartilage precursor cells, lymphoid precursor cells, NK precursor cells, embryonic stem cells, etc., among which osteoblasts, chondrocytes, adipocytes
- Mesenchymal stem cells which are undifferentiated cells that have the potential to differentiate into cells such as muscle cells, tendon cells, periodontal ligament, cementum, or promote their repair, should be listed as suitable targets.
- the cell proliferation method of the present invention includes a cell differentiation-inducing culture method.
- the differentiation-inducing culture of mesenchymal stem cells is performed by the method described in JP-A-2003-52360. Can be.
- the target cells When cells are grown in vivo, such as in a non-human animal, by adding the cell growth agent of the present invention locally, the target cells can be grown while suppressing the growth of contaminating microorganisms.
- it can be added in the form of a DNA vector capable of expressing a cell growth agent such as an antimicrobial peptide.
- the basic antibacterial peptide of the present invention can be prepared by a genetic engineering technique, but can also be chemically synthesized by a peptide synthesis method.
- a liquid phase method and a solid phase method for peptide synthesis are a method in which a reaction is carried out in a solution state, a product is isolated and purified from a reaction mixture, and this product is used as an intermediate for the next peptide extension reaction.
- the solid phase method is a method in which an amino acid is bound to a solid support insoluble in a reaction solvent, and a condensation reaction is performed in accordance with the amino acid to elongate the peptide chain.
- the amino acid protected with a carboxyl group is dehydrated and condensed with an amino acid protected with an amino group to form a peptide bond. After the amino protecting group is removed, the released amino group is removed.
- the basic method is to sequentially extend the next amino-protected amino acid one by one from the C-terminal to the N-terminal.
- a carboxyl group is activated and reacted with an amino group to be bonded.
- This activation includes a dicyclohexylcarbodiimide (DCC) method, an active ester method, an acid anhydride method, an azide method, etc., and is selected in consideration of its high reactivity, racemization and other side reactions.
- DCC dicyclohexylcarbodiimide
- active ester method an acid anhydride method
- azide method etc.
- protective groups are introduced into the amino group, carboxyl group, and functional group of the side chain (R) of amino acids. The It is preferred that these protecting groups are stable under the conditions of the condensation reaction and are promptly removed when necessary. It is preferable that the protecting group for the amino group and the protecting group for the carboxyl group are selectively removed from each other.
- Examples of the protecting group for an amino group include benzyloxycarbol (Bz), t-butyloxycarbol (Boc), p-biphenylisopropylpropoxycarbol, and 9-fluormethyl. Oxycarbol (fmoc) and the like.
- Examples of the protecting group for the carboxy group include groups capable of forming an alkyl ester, a benzyl ester and the like. However, in the case of the solid phase method, the carboxyl group at the C-terminus is bonded to a carrier such as black mouth trityl resin, chloromethyl resin, oxymethyl resin, and P alkoxybenzyl alcohol resin.
- the condensation reaction is carried out in the presence of a condensing agent such as carbodiimide or using an N-protected amino acid active ester or peptide active ester. After completion of the condensation reaction, the protecting group is removed, but in the case of a solid phase, the bond between the C-terminal of the peptide and the resin is further cleaved.
- the chemically synthesized peptide is purified by a usual method, for example, ion exchange chromatography, reverse phase liquid chromatography, affinity chromatography and the like.
- the synthesized peptide can be analyzed by a protein sequencer that reads the amino acid sequence from the C-terminal by the Edman degradation method, GCMS, or the like.
- the antimicrobial peptide of the present invention can also be prepared using genetic engineering techniques.
- a genetic engineering technique for example, a host cell which has been synthesized with a DNA sequence encoding the novel peptide of the present invention and transformed or transformed with an expression vector into which a gene comprising the DNA sequence has been inserted is used. To produce a new peptide.
- Either eukaryotic cells or prokaryotic cells can be used as host cells used in the genetic engineering technique.
- Eukaryotic cells include cells of animals, plants, insects, yeasts, and the like, and prokaryotic cells include appropriate host cells such as Escherichia coli, Bacillus subtilis, and actinomycetes.
- an appropriate vector suitable for a known host cell can be used as a vector used in the genetic engineering technique.
- the antimicrobial peptide of the present invention can also be used in the form of a pharmaceutically acceptable derivative or salt.
- the derivative of the antimicrobial peptide is a peptide derivative such as a partially substituted antimicrobial peptide or an additional compound.
- Rui-done derivatives can be given.
- strong salts include inorganic salts such as hydrochloride, nitrate and hydrobromide, and salts such as P-toluenesulfonate, metasulfonate, fumarate, succinate and lactate. Organic acid salts and the like can be mentioned.
- Z or the cell growth promoter can be used in combination with another antibacterial agent and Z or the cell growth promoter.
- the antibacterial agent of the present invention can be used as a pharmaceutical composition or food.
- the pharmaceutical composition includes both pharmaceuticals and quasi-drugs. These can be made into various dosage forms such as tablets, granules, powders, gels, capsules, suspensions, injections, suppositories, liquids, ointments, and external preparations by a conventional method.
- These pharmaceutical compositions can be produced by mixing the antimicrobial peptide or a pharmaceutically acceptable salt thereof with a protease inhibitor and, if necessary, a pharmaceutically acceptable carrier.
- an excipient, a binder, a disintegrating agent, a bulking agent, a coating agent, a sugar coating agent, etc. are added to an antimicrobial peptide or the like, if necessary, and the preparation is produced by a conventional method. be able to.
- it may be in the form of a preparation in which an antimicrobial peptide or the like is included by ribosomes or the like.
- a liquid preparation it can be in the form of a solution, suspension, emulsion or the like buffered with various salts and buffers.
- the salt examples include an alkali or alkaline earth halide, a phosphate, or a sulfate such as sodium chloride, potassium potassium, or sodium sulfate.
- a buffer for example, citrate, phosphate, HEPES, Tris and the like can be used to the extent that such a buffer is to be treated, in a physiologically acceptable degree to the subject to be treated.
- the antimicrobial peptide or the like may be dissolved in an aqueous carrier such as distilled water for injection, dispersed, emulsified, or the like in advance to give a liquid for injection, or may be made into a powder for injection and dissolved at the time of use.
- the administration method is not particularly limited, and it can be administered in various modes depending on the form of the pharmaceutical composition, the properties of the administration subject, and the like.
- oral, intravenous, subcutaneous, transdermal, intramuscular, intraperitoneal, nasopharyngeal, etc. administration are possible.
- the foods can be in any form, such as drinks such as juices and teas; gel-like foods such as udon, buckwheat, tofu, power maboko, and jelly. These can be produced according to a conventional method by adding an antimicrobial peptide or the like to the raw material of each food.
- TANA laboratories., Texas, USA requested chemical synthesis of seven basic antimicrobial peptides by solid-phase synthesis using the fmoc method.
- HATU-N, N-dimethylformamid was used as a condensing agent in the solid phase synthesis method by the fmoc method.
- the product was prepared by HPLC and reversed-phase chromatography, and the molecular weight was confirmed by Mass spectrometry (Matrix Assisted Laser Desorption lonization-TOF / MS), so-called Tofmas.
- JH8944 basic antibacterial peptide of the present invention SEQ ID NO: 1 in the S column list: FKCKKWISLRR Y (Phe Lys Lys Lys Val Vallle Ser Leu Arg Arg Tyr j) was obtained.
- the test of bactericidal activity was performed by the method of Edgerton et al. (Edgerton M, Koshlukova SE, Lo TE, Cnrzan Bu, Strau 3,r RM, Raj PA. Candidacidal activity of salivary histatins.
- Basic antimicrobial peptide synthesized by the ftnoc method.
- Rabbit mesenchymal stem cells Collected from rabbit iliac bone
- Cell growth medium MEM medium with serum
- Cell growth culture conditions 5% CO, 37 ° C
- Cell counting method The amount of intracellular ATP was measured by a luciferin / luciferase reaction.
- antimicrobial peptide JH8944
- cell proliferation effects on rabbit mesenchymal cells rabbit mesenchymal cells (rabitMS C), human gingival fibroblasts (HGFB), and rat embryoZietus-derived (3Y1) were examined.
- concentration of each peptide was set at 0 to 10/1111, and the cell proliferation at a concentration of 0 was set as 100, and the relative ratio was examined.
- Cells were cultured using DMEM medium, and peptides were added in the late logarithmic growth phase.
- FIG. 2-A, FIG. 2-B Furthermore, the antimicrobial peptide of the present invention significantly promoted cell proliferation, and showed about 200% of the proliferation effect as compared with the case where no antimicrobial peptide was added.
- FIG. 1 shows the results of a test on the bactericidal activity of the antimicrobial peptide of the present invention against S. mutans in the examples of the present invention.
- FIG. 1 is a diagram showing the bactericidal rate against S. mutans 0-5.
- FIG. 2 In an example of the present invention, a rabbit mesenchymal cell (rabitMSC), a human gingival fibroblast (HGFB), and a rat embryoZfetus-derived (3Y1) were used using the antimicrobial peptide of the present invention (JH8944).
- FIG. 3 is a view showing the results of examining the cell growth effect on.
- rabbit mesenchymal cells (rabit)
- FIG. 1 is a graph showing the results of tests on the bactericidal activity of the antimicrobial peptide of the present invention against S. mutans in the examples of the present invention.
- FIG. 2 In the examples of the present invention, cells against rabbit mesenchymal cells (rabitMSC), human gingival fibroblasts (HGFB), and rat embryoZfetus-derived (3Y1) using the antibacterial peptide CFH8944) of the present invention. It is a figure which shows the result of having examined the proliferation effect.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Materials For Medical Uses (AREA)
- Cosmetics (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-098896 | 2004-03-30 | ||
JP2004098896A JP2005281225A (ja) | 2004-03-30 | 2004-03-30 | 新規塩基性抗菌ペプチド及びその利用 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005095445A1 true WO2005095445A1 (ja) | 2005-10-13 |
Family
ID=35063724
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/005724 WO2005095445A1 (ja) | 2004-03-30 | 2005-03-28 | 新規塩基性抗菌ペプチド及びその利用 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP2005281225A (ja) |
WO (1) | WO2005095445A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2682463A1 (en) * | 2011-02-10 | 2014-01-08 | Hiroshima University | Bacteriocin derived from lactobacillus rhamnosus |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995028832A1 (en) * | 1994-04-20 | 1995-11-02 | Demeter Biotechnologies, Ltd. | Method of enhancing wound healing by stimulating fibroblast and keratinocyte growth in vivo, utilizing amphipathic peptides |
WO2002079408A2 (en) * | 2001-03-28 | 2002-10-10 | Helix Biomedix, Inc. | Short bioactive peptides and methods for their use |
-
2004
- 2004-03-30 JP JP2004098896A patent/JP2005281225A/ja active Pending
-
2005
- 2005-03-28 WO PCT/JP2005/005724 patent/WO2005095445A1/ja active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995028832A1 (en) * | 1994-04-20 | 1995-11-02 | Demeter Biotechnologies, Ltd. | Method of enhancing wound healing by stimulating fibroblast and keratinocyte growth in vivo, utilizing amphipathic peptides |
WO2002079408A2 (en) * | 2001-03-28 | 2002-10-10 | Helix Biomedix, Inc. | Short bioactive peptides and methods for their use |
Non-Patent Citations (1)
Title |
---|
HONG S.Y. AND PARK T.G. ET AL: "The effect of charge increased on the specifity and activity of a short antimicrobial peptide.", PEPTIDES., vol. 22, no. 10, 2001, pages 1669 - 1674, XP002990333 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2682463A1 (en) * | 2011-02-10 | 2014-01-08 | Hiroshima University | Bacteriocin derived from lactobacillus rhamnosus |
EP2682463A4 (en) * | 2011-02-10 | 2014-11-26 | Univ Hiroshima | BACTERIOZIN OBTAINED FROM LACTOBACILLUS RHAMNOSUS |
Also Published As
Publication number | Publication date |
---|---|
JP2005281225A (ja) | 2005-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kang et al. | Structure–biological activity relationships of 11‐residue highly basic peptide segment of bovine lactoferrin | |
CN111944057B (zh) | 一种重组人胶原蛋白肽及其应用 | |
US5696078A (en) | Methods of treating fungal infections using histatin-based peptides | |
AU633832B2 (en) | Novel antimicrobial peptide, compositions containing same and uses thereof | |
Pepperney et al. | Antibacterial peptides: opportunities for the prevention and treatment of dental caries | |
KR100393508B1 (ko) | 인간 인터루킨 4의 안타고니스트 또는 부분적 아고니스트로서의 신규hIL-4 변이단백질 | |
CA2032059C (en) | Wound treatment employing biologically active peptides | |
US5424396A (en) | Antimicrobial peptide and antimicrobial agent | |
US7482328B2 (en) | Antimicrobial polypeptide and utilization thereof | |
KR101675525B1 (ko) | 락토바실러스 람노서스 유래의 박테리오신 | |
CA2319094C (en) | Antimicrobial peptides | |
RU94046367A (ru) | Днк, хозяйская клетка, способ получения белка, белок, фармацевтический препарат, антитело, применение антитела | |
JP4730584B2 (ja) | 抗菌ペプチド及びその利用 | |
JP4293889B2 (ja) | 塩基性抗菌性ペプチドを有効成分とする細胞増殖剤 | |
JP4932731B2 (ja) | シグナルペプチド、核酸分子及び治療方法 | |
JP4520477B2 (ja) | 抗真菌ペプチドまたはそれを含有するペプチド組成物とその製造方法 | |
CA2285673C (en) | Cyclic analogs of histatins | |
US20090030179A1 (en) | Antimicrobial peptide and use thereof | |
CN111423516B (zh) | 一种蛋白及其在创口修复及抑菌中的应用 | |
EP2114989A2 (en) | Natural polypeptides for oral health care | |
US7485622B2 (en) | Paralytic peptide for use in neuromuscular therapy | |
JP4817335B2 (ja) | 新規抗菌性ペプチド | |
WO2005095445A1 (ja) | 新規塩基性抗菌ペプチド及びその利用 | |
JPWO2012081531A1 (ja) | 疾病抑制剤 | |
US5969098A (en) | Yeast-toxin-related protein for antimicrobial vaccine and sterilizing preservative use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
122 | Ep: pct application non-entry in european phase |